Same Indication

Pembrolizumab vs Tositumomab

Pembrolizumab vs Tositumomab: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Tositumomab.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Pembrolizumab β€” 26 days.

Chemical Properties

Type: Pembrolizumab β€” Antibody; Tositumomab β€” Antibody.